FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... The near-10% compound annual growth rate predicted by the analysts reflects the late-phase pipeline.

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

The DehydraTECH-tirzepatide test articles were compound formulated using Zepbound®, strictly for research purposes, and dosed orally to the subjects under fasted conditions. The Study was ...

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Zepbound, which was only introduced in November ... the pharma has grown its dividend at an 18% compound annual growth rate over the last five years and just recently announced a new 15% increase.

Novo Nordisk made a similar case for semaglutide in a petition to the regulator last year, seeking to put the drug on an FDA list of compounds deemed to be difficult to compound, but has so far ...

But compound pharmacies and their products "fall ... Rybelsus), tirzepatide (Mounjaro, Zepbound), or liraglutide (Victoza, Saxenda), or a prescription for such. All websites sold compounded ...